CIMFLOVÁ, Petra, E. ÖZLÜK, B. KORKMAZER, R. AHMADOV, E. AKPEK, O. KIZILKILIC, C. ISLAK and N. KOCER. Long-term safety and efficacy of distal aneurysm treatment with flow diversion in the M2 segment of the middle cerebral artery and beyond. Journal of NeuroInterventional Surgery. London: BMJ PUBLISHING GROU, 2021, vol. 13, No 6, p. 631-636, 7 pp. ISSN 1759-8478. Available from: https://dx.doi.org/10.1136/neurintsurg-2020-016790.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Long-term safety and efficacy of distal aneurysm treatment with flow diversion in the M2 segment of the middle cerebral artery and beyond
Authors CIMFLOVÁ, Petra (203 Czech Republic, belonging to the institution), E. ÖZLÜK (792 Turkey), B. KORKMAZER (792 Turkey), R. AHMADOV (792 Turkey), E. AKPEK (792 Turkey), O. KIZILKILIC (792 Turkey), C. ISLAK (792 Turkey) and N. KOCER (792 Turkey, guarantor).
Edition Journal of NeuroInterventional Surgery, London, BMJ PUBLISHING GROU, 2021, 1759-8478.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.572
RIV identification code RIV/00216224:14110/21:00121122
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1136/neurintsurg-2020-016790
UT WoS 000667295800013
Keywords in English distal aneurysm treatment; middle cerebral artery
Tags 14110119, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 17/5/2022 08:40.
Abstract
Background Indications for flow diversion stent (FDS) treatment are expanding. However, there is still a lack of evidence for the long-term outcome in distally located aneurysms in the M2 segment of the middle cerebral artery (MCA) and beyond. Methods Consecutive subjects (from June 2013 to August 2020) with MCA aneurysms in the M2 segment or beyond treated with FDS were reviewed retrospectively. The primary endpoints for clinical safety were the absence of mortality, stroke event, re-rupture of the aneurysm, and worsening of clinical symptoms. The primary endpoint for treatment efficacy was complete/near-complete occlusion at follow-up after 12 months. Results 23 patients were identified: 7 aneurysms were located in the M2 segment of the MCA, 4 in the M2-M3 bifurcation, 2 in M3, 3 in M3-4 branching, and 2 in M4; 5 aneurysms were located in M2 with extension into the M1-M2 bifurcation. 13 aneurysms were of fusiform morphology, 8 sacculofusiform, and 2 saccular. 16 aneurysms were of highly suspected dissecting etiology. The median diameter of the parent vessel was 2.1 mm proximally and 2 mm distally. The median time of the follow-up was 30 months (range 16 months to 6 years). Complete/near complete occlusion was observed in 14/20 patients (70%) and one stable remodeling (5%) was seen at 12 months. 22 patients (95.6%) had an excellent clinical outcome (mRS 0–1) at 6 months. Technical challenges associated with the deployment of FDS occurred in 8.7% of cases. Severe complications, intraparenchymal hemorrhage and re-rupture of the aneurysm occurred in 2 patients (8.7%).
PrintDisplayed: 8/9/2024 19:21